For instance, trabectedin, which has been used to treat human ovarian cancer and myxoid liposarcoma in clinic, mechanistically acts by blocking macrophage recruitment through the targeting of monocyte chemoattractant protein‐1 (MCP‐1/CCL2), which correlates with increased macrophage infiltration.4, 5, 6. Here, CCL2 is linked to myxoid liposarcoma.